



**PATENT**

Docket No.: FRAV2003/0002 US NP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Patek, Marcel et al.

Examiner: Not yet assigned

Application No.: 10/770,382

Art Unit: 1614

Filed: February 2, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Title: Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof As Kinase Inhibitors

Date of Deposit

Signature

**CORRECTION OF INVENTORSHIP IN A PATENT**  
**APPLICATION UNDER 37 C.F.R. §1.48(a)**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is an amendment to correct an error in the nonjoinder of inventors in the above patent application. Enclosed please find the required documents for support:

- (1) A request, pursuant to 37 CFR §1.48 (a)(1), to correct the inventorship that sets forth the desired inventorship change.
- (2) A statement, pursuant to 37 C.F.R. §1.48(a)(2), from Didier Benard who is being added as an inventor;
- (3) A declaration by the actual inventors; pursuant to 37 C.F.R. §1.48(a)(3)
- (4) Pursuant to 37 C.F.R. §1.48(a)(4), the processing fee set forth in 37 C.F.R. §1.17(i)
- (5) The written consent of the assignee, Aventis Pharma S.A., pursuant to 37 CFR §1.48(a)(5);
- (6) A statement under 37 CFR §3.73(b), establishing the right of assignee to take action, further including the statement that establishes the right of the assignee to take action regarding the instant patent application; and
- (7) An assignment, concurrently submitted herewith for recordal, signed by Didier Benard

04/25/2005 BABRAHA1 00000008 181982 10770382

01 FC:1464

130.00 DA

Docket No.: FRAV2003/0002 US NP

Page 1 of 2